Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for high-risk acute leukemia following allogeneic stem cell transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

BOBetül OranGAGheath AlatrashRBRoland L. Bassett

Discussion

Loading...

Member takes

Overview

Clinical trial shows improved relapse-free survival in high-risk AML patients, highlighting potential of venetoclax and azacitidine post-transplant.

Key Points

  • Relapse-free survival was 63.3% at 1 year in patients receiving maintenance therapy post-transplant.
  • Overall survival rates reached 82.5% at 1 year, indicating promising outcomes for high-risk AML.
  • Phase II clinical trial demonstrated safety and tolerability despite common grade 3-4 toxicities like neutropenia and anemia.
  • Further research is needed to confirm these findings and explore effects in intermediate risk AML cohorts.

Cite This Study

Oran et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e538https://doi.org/10.1182/blood-2025-2511
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for acute lymphoblastic leukemia following allogeneic stem cell transplantation2025
  2. 2Venetolax plus azacitidine is effective maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with intermediate/high-risk Acute Myeloid Leukemia2025
  3. 3Azacitidine combined with Venetoclax for pre-emptive treatment of AML/MDS after allogeneic stem cell transplantation: A prospective phase II study2025
  4. 4A pre-emptive bridge-to-transplant therapy for measurable residual disease with venetoclax and azacitidine in NPM1-mutated Acute Myeloid Leukemia: Updates from the ongoing GIMEMA AML2521 phase 2 trial2025
  5. 5A Phase 1B/2A study of weekly decitabine and venetoclax treatment as maintenance therapy in high-risk myeloid malignancy patients post allogeneic stem cell transplantation2025